These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 31957251

  • 1. Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
    Li W, Bai R, Qian L, Chen N, Zhao Y, Han F, Bai L, Li J, Yu Y, Cui J.
    Asia Pac J Clin Oncol; 2021 Apr; 17(2):e40-e47. PubMed ID: 31957251
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.
    Mu L, Liu F, Fang Y, He M, Yang M.
    BMJ Open; 2024 Aug 22; 14(8):e081270. PubMed ID: 39179275
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu Q, Liang M, Zhou X, Ding Z, Huang M, Ren L, Zhu J, Li L, Hou M, Ding L, Tan F, Lu Y.
    Lung Cancer; 2016 Jun 22; 96():93-100. PubMed ID: 27133757
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Fan Y, Huang Z, Fang L, Miao L, Gong L, Yu H, Yang H, Lei T, Mao W.
    Cancer Chemother Pharmacol; 2015 Sep 22; 76(3):517-23. PubMed ID: 26148750
    [Abstract] [Full Text] [Related]

  • 7. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JS.
    PLoS One; 2021 Sep 22; 16(3):e0247860. PubMed ID: 33647045
    [Abstract] [Full Text] [Related]

  • 8. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 22; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 9. Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.
    Zhang C, Zhang H, Shi J, Wang D, Zhang X, Yang J, Zhai Q, Ma A.
    PLoS One; 2016 Sep 22; 11(3):e0151846. PubMed ID: 27015267
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B, Chen H, Shen J, Ye M.
    Clin Ther; 2011 Oct 22; 33(10):1446-55. PubMed ID: 21992806
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L, Hu H, Liao M, Xia X, Shi Y, Yao L, Ding D, Zhu Y, Zeng S, Shen L, Huang J, Carbone DP.
    Lung Cancer; 2019 Dec 22; 138():88-94. PubMed ID: 31655368
    [Abstract] [Full Text] [Related]

  • 12. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.
    Health Technol Assess; 2010 Oct 22; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.
    Lung Cancer; 2015 Oct 22; 90(1):71-7. PubMed ID: 26259876
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Med Oncol; 2016 Aug 22; 33(8):97. PubMed ID: 27447711
    [Abstract] [Full Text] [Related]

  • 15. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X, Chen X, Li H, Liu X, Li Y.
    Front Public Health; 2023 Aug 22; 11():1054405. PubMed ID: 36923040
    [Abstract] [Full Text] [Related]

  • 16. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
    Fan Y, Xu Y, Gong L, Fang L, Lu H, Qin J, Han N, Xie F, Qiu G, Huang Z.
    Sci Rep; 2017 Mar 23; 7():45193. PubMed ID: 28332624
    [Abstract] [Full Text] [Related]

  • 17. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.
    Health Technol Assess; 2015 Jun 23; 19(47):1-134. PubMed ID: 26134145
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
    Lester-Coll NH, Dosoretz AP, Magnuson WJ, Laurans MS, Chiang VL, Yu JB.
    J Neurosurg; 2016 Dec 23; 125(Suppl 1):18-25. PubMed ID: 27903191
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N, Zhang Q, Fang S, Han X, Wang Z.
    Oncotarget; 2017 Feb 07; 8(6):9134-9143. PubMed ID: 27852073
    [Abstract] [Full Text] [Related]

  • 20. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
    Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q, Yi L.
    PLoS One; 2014 Feb 07; 9(2):e88881. PubMed ID: 24586426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.